Compare GABC & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | ALMR |
|---|---|---|
| Founded | 1910 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1995 | 2026 |
| Metric | GABC | ALMR |
|---|---|---|
| Price | $49.77 | $28.61 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $47.67 | N/A |
| AVG Volume (30 Days) | 94.6K | ★ 261.2K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 8.13 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $487,401,000.00 | N/A |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $26.18 | ★ N/A |
| Revenue Growth | ★ 37.80 | N/A |
| 52 Week Low | $37.19 | $21.58 |
| 52 Week High | $52.23 | $38.54 |
| Indicator | GABC | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 41.84 |
| Support Level | $48.85 | $23.69 |
| Resistance Level | $51.97 | $28.35 |
| Average True Range (ATR) | 0.80 | 1.94 |
| MACD | -0.05 | -0.69 |
| Stochastic Oscillator | 69.15 | 9.57 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.